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Abstract: Despite the significant improvements in the pharmacology of muscle relaxants 
in the past six decades, the search for the ideal muscle relaxant continues, mainly because of 
the incomplete efficacy and persistent side effects associated with their antagonism. Clinical 
concerns remain about the residual paralysis and hemodynamic side effects associated with 
the classic pharmacologic reversal agents, the acetylcholinesterase inhibitors. Although the 
development of the “ideal muscle relaxant” remains illusory, pharmacologic advancements 
hold promise for improved clinical care and patient safety. Recent clinical advances include 
the development of short-acting nondepolarizing muscle relaxant agents that have fast onset 
and a very rapid metabolism that allows reliable and complete recovery; and the development 
of selective, “designer” reversal agents that are specific for a single drug or class of drugs. This 
article reviews recent developments in the pharmacology of these selective reversal agents: 
plasma cholinesterases, cysteine, and sugammadex. Although each of the selective reversal 
agents is specific in its substrate, the clinical use of the combination of muscle relaxant with its 
specific reversal agent will allow much greater intraoperative titrating ability, decreased side 
effect profile, and may result in a decreased incidence of postoperative residual paralysis and 
improved patient safety.
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Arguably, one of the most significant developments in surgery over the past century 
has been the introduction of muscle relaxation provided by the administration of 
neuromuscular blocking drugs. While initially the use of curare was reported to be 
associated with significant perioperative morbidity and mortality,1 at the same time, 
the provision of markedly improved surgical conditions (flaccid paralysis) afforded 
by muscle relaxants has allowed significant advances in surgery.
The first administration of anesthesia via a tracheostomy by Friedrich Trendelenburg 
in 18712 was followed soon by the first report of endotracheal intubation for anesthesia 
by William MacEwen in 1880 to prevent aspiration of blood during oral surgery.3 
Although orotracheal intubation did not become routine in clinical medicine until 
the 1940s, its use further improved the safety of the newly introduced neuromus-
cular blocking agents (NMBAs) by allowing positive pressure ventilation. The last 
three decades have been witness to a significant increase in the number of NMBAs 
introduced into clinical care in an attempt to reduce the side effect profile, decrease 
their onset time for rapid management of the airway, shorten their duration of action, Drug Design, Development and Therapy 2009:3 120
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and hasten their rapid recovery. In other words, numerous 
attempts have been made to develop the “perfect” muscle 
relaxant.4
To some limited extent, the search for this “perfect” agent 
has been successful, although no current NMBA possesses all 
of the qualities of the ideal agent. Succinylcholine is rapid in 
onset, reliable in producing good intubating conditions, and 
relatively short in duration of action. Unfortunately, its many 
side effects limit its usefulness in some clinical situations and 
age groups. Rocuronium in large doses is also rapid in onset, 
and does not have some of the side effects (hyperkalemia, 
myalgia, malignant hyperthermia triggering) that limit the 
use of succinylcholine. Rocuronium, however, has a long and 
unpredictable duration of action after administration of large 
doses required for rapid sequence intubation, thus introducing 
a different set of patient safety concerns in those patients in 
whom mask ventilation and tracheal intubation are difficult or 
impossible. Equally problematic is the continued occurrence 
of residual weakness (the so-called “residual curarization”) 
in patients who receive NMBAs, despite administration of 
adequate doses of reversal agents and even in patients deemed 
“fully recovered” by clinicians. In fact, residual paralysis 
continues to be reported, despite the change in the definition 
of “adequate recovery” from a train-of-four (TOF) ratio of 
0.70 to the current TOF ratio value of 0.90.5,6
The literature is replete with case reports and clinical 
studies that have attempted to delineate the frequency with 
which residual neuromuscular effects are still present in 
postoperative patients following tracheal extubation. Recent 
reports7–10 have documented that residual paralysis in the 
postoperative period is not benign: 8 of 7,459 patients (0.1%) 
required emergent tracheal reintubation in the postoperative 
care unit (PACU) for respiratory insufficiency after tracheal 
extubation in the operating room.7 Clearly, a considerable 
number of patients continue to be at significant risk of mor-
bidity and mortality.
It is thus clear that despite advances in the pharmacology 
of NMBAs, our current understanding of the need for 
perioperative neuromuscular monitoring of pharmacologic 
reversal is inadequate. Part of this limitation is due to the 
mechanism of action of classic reversal agents: by blocking 
acetylcholinesterases, traditional reversal agents allow an 
increase in the concentration of acetylcholine (ACh) at the 
neuromuscular junction, which then competes effectively 
(in most, but not all, cases) with the nondepolarizing muscle 
relaxant for the post-synaptic receptor recognition sites. The 
increase in the concentration of ACh at the neuromuscular 
junction, however, is limited by the amount of ACh that is 
degraded by acetylcholinesterases. Once the enzymes are 
inhibited maximally (and ACh is no longer degraded), the 
concentration of ACh at the neuromuscular junction reaches 
a maximum. In those cases in which this maximal concen-
tration of ACh is still insufficient to compete effectively 
with the nondepolarizing muscle relaxant, the competition 
for receptor binding favors the relaxant, and neuromuscular 
block ensues.
Some depolarizing agents (eg, succinylcholine), as well 
as nondepolarizing muscle relaxants (eg, mivacurium), are 
naturally metabolized by plasma cholinesterases. In patients 
who have atypical plasma cholinesterases, the metabolism 
of these drugs is markedly prolonged. However, intravenous 
administration of human cholinesterase results in rapid 
reversal of neuromuscular block.11,12
Another potential mechanism that is more efficient in 
terminating the effects of NMBAs at the neuromuscular 
junction is the very rapid, nonenzymatic breakdown of some 
NMBAs that occurs in the presence of naturally occurring 
amino acids such as cysteine and glutathione.13 The prototype 
of this kind of amino acid is cysteine, which can be used to 
very rapidly terminate the neuromuscular blocking action 
of a new class of relaxants, the asymmetric mixed-onium 
chlorofumarates gantacurium (GW280430A, also known 
as AV430A)14 and AV002 (CW002).15 These compounds 
have undergone initial animal testing (gantacurium), or are 
scheduled to start testing in 2009 (AV002).
More efficient mechanisms for termination of the actions 
of nondepolarizing agents would constitute a significant 
advance in the pharmacology of muscle relaxants and the 
safety of clinical care. Conceptually, the direct inhibition of 
the NMBA activity at the effect site is a much more efficient 
mechanism of reversal, rather than reliance on ACh competi-
tion for receptor recognition sites. This proposed mechanism 
was used to develop a new class of NMBA reversal agents: 
the selective relaxant binding agent (SRBA).16 The prototype 
of this selective reversal agent is sugammadex.
Human plasma cholinesterase
Pharmacology
Cholinesterases are enzymes that catalyze the hydrolysis 
of the neurotransmitter acetylcholine (ACh). There are two 
types of cholinesterases: the acetylcholinesterase (AChE, also 
known as red blood cell cholinesterase), whose main sub-
strate is ACh; and pseudocholinesterase (also called plasma 
cholinesterase or butyrylcholinesterase [BChE]), whose main 
substrate is butyrylcholine. In humans, the absolute level 
(quantity) and activity (quality) of plasma cholinesterases are Drug Design, Development and Therapy 2009:3 121
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determined by several genetic variations, leading to a large 
number of genotypes and phenotypes.17,18 Human BChE has 
been sequenced, and has been shown to contain four identical 
subunits (tetramer); each subunit contains 574 amino acids, 
and the tetramer has a total weight of 342,000 Da.19 BChE 
is synthesized in the liver.
Pseudocholinesterase deficiency
A genetically inherited abnormality most common in people 
of European descent, pseudocholinesterase deficiency results 
in pseudocholinesterases (BChE) with abnormally slow 
ability to metabolize exogenous choline esters. The condition 
results in abnormally prolonged action of drugs that undergo 
hydrolysis of choline esters: succinylcholine, mivacurium, 
procaine, and cocaine.20
Acquired cases of cholinesterase deficiency usually result 
in a very similar clinical picture as the hereditary disease. Some 
of the causes of acquired pseudocholinesterase deficiency due 
to low cholinesterase activity include certain physiologic 
conditions (extremes of age, pregnancy); chronic infections 
(tuberculosis); alcohol abuse and liver disease (low hepatic 
synthetic function); extensive burn injury; malnutrition; 
renal failure and uremia; malignancy; and iatrogenic 
causes (plasmapheresis; organophosphate poisoning, 
echothiophate ophthalmic drops; anticholinesterase inhibitor 
therapy; monoamine oxidase inhibitors; glucocorticoids, 
contraceptive therapy).
Antagonism of neuromuscular block
In patients with acquired or hereditary pseudocholinesterase 
deficiency, the metabolic hydrolysis of succinylcholine and 
mivacurium are greatly impaired, resulting in prolonged 
muscle paralysis (4–8 hours). Human plasma cholinesterase 
administration has been shown to significantly decrease the 
duration of succinylcholine and mivacurium block (5–10 min 
and 30 min, respectively) in these patients.11,21
Pharmacokinetics and pharmacodynamics
In normal patients receiving succinylcholine, approximately 
90%–95% of the intravenous dose will be hydrolyzed in 
the plasma before reaching the neuromuscular junction, 
resulting in a short (4–10 min) duration of action. In 
patients with pseudocholinesterase deficiency, most of 
the administered succinylcholine will not be metabolized 
and will reach the neuromuscular junction, resulting in 
markedly prolonged (4–8 hours) neuromuscular block. 
Mivacurium is also metabolized by BChE at a rate that 
is approximately 70%–75% of the rate of succinylcholine 
metabolism.22 In patients phenotypically heterozygous for 
pseudocholinesterase deficiency who received mivacurium, 
the duration of neuromuscular block, defined as return of 
TOF ratio to 0.7, was prolonged (30 min).23 In patients 
homozygous for atypical cholinesterase, the recovery was 
even longer, 30–60 min.21 In phenotypically normal patients, 
the duration of action of mivacurium can be predicted based 
on the patients’ cholinesterase activity; thus, in patients 
with BChE activity below the normal range, recovery from 
mivacurium is slightly prolonged.24
When administered intravenously to patients homozygous 
for the atypical gene for plasma cholinesterase, the half-
life of BChE is approximately 11 days; it has a volume of 
distribution of 14%–18% of body weight.25
Treatment
Human plasma cholinesterase has been available commercially 
for well over 30 years.26 Human BChE can be purchased in 
5- and 10-unit lots, where one unit corresponds to the amount 
of enzyme that will hydrolyze one micromole of butyryl-
choline substrate per minute at 37°C and pH of 8.0. As of 
2009, the cost for a 5-unit dose was $220, and for the 10-unit 
dose it was $400 (BioPur AG, Bubendorf, Switzerland). The 
highly purified native proteins are reported to be free from 
potential contaminants such as hepatitis virus or HIV, and 
no hypersensitivity reactions have been described.12
Since cocaine is metabolized by cholinesterases, individu-
als with pseudocholinesterase deficiency may be at increased 
risk of toxic reactions, arrhythmias, myocardial infarction, 
stroke and death associated with recreational use of cocaine.27 
In laboratory animals, the prophylactic administration of 
human plasma cholinesterase protects against the convulsive 
and lethal effects of cocaine overdose.28
Prophylactic transfusion of fresh frozen plasma can 
sometimes improve the patient’s own plasma cholinesterase 
activity. However, the risk of transfusion-related infection 
outweighs the benefits and is not recommended. Administration 
of cholinesterase inhibitors such as neostigmine is contro-
versial, as the effect is variable, improvement (if any) is 
transient, and may be followed by an increase in the degree 
of neuromuscular block.29 In the absence of readily available 
human plasma cholinesterase, mechanical ventilatory support 
(with analgesia and amnesia) is the recommended treatment 
until the return of spontaneous respiratory muscle function.
In patients with normal cholinesterase activity levels, 
the administration of human plasma cholinesterase results 
in reversal of mivacurium-induced block that is similar to 
that induced by edrophonium. However, the combination of Drug Design, Development and Therapy 2009:3 122
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edrophonium and human plasma cholinesterase significantly 
accelerates recovery of mivacurium-induced block.30 When 
comparing the anticholinesterase neostigmine with human 
plasma cholinesterase for mivacurium and succinylcholine 
reversal, neostigmine was an incomplete reversal drug, and 
at pharmacologic concentrations, it actually inhibited the 
effects of plasma cholinesterase.29
Cysteine
Pharmacology
A semi-essential (or conditionally essential) amino acid, 
cysteine can be synthesized from the essential amino acid 
methionine and the nonessential amino acid serine by the 
process of trans-sulfuration31 (Figure 1). In this pathway, 
cysteine is formed when methionine donates the sulfur 
to serine. Cysteine has two stereoisomers that are not 
superimposable mirror images (enantiomers): the l- and 
the d-enantiomers. Of the two, the l-cysteine enantiomer 
acts as a precursor amino acid for the synthesis of several 
proteins such as coenzyme A and γ-glutamylcysteinylgly-
cine. The extent of racemization of l-amino acid residues 
to the d-enantiomers in food proteins increases with pH, 
time, and temperature.32 Since d-amino acids are, in general, 
deleterious, d-cysteine (whether ingested or formed in the 
body) imposes a metabolic burden on the organism and could 
therefore be considered toxic.32
l-cysteine and its oxidized counterpart, cystine, are 
rate-limiting precursors in the synthesis of glutathione. In 
fact, cysteine is stored in the body as glutathione (which 
may be hydrolyzed to generate cysteine if needed), which 
may explain the low tissue concentration of cysteine.33 Glu-
tathione also serves as a means for transporting cysteine to 
extrahepatic tissues.33
Safety
l-cysteine is a sulfate donor in detoxification reactions.34 
Because of its participation in detoxification, it has important 
neuroprotective roles.35 Another mechanism of neuro-
protection by l-cysteine is the interference it provides to 
the entry of potentially injurious heavy metal ions across 
the blood–brain barrier.36 Despite these neuroprotective 
effects, however, l-cysteine can also be neurotoxic in high 
concentrations. Administration of exogenous l-cysteine is 
excitatory, and its neurotoxic effects have been implicated 
in several neurological disorders such as Parkinson’s, 
Alzheimer’s, amyotrophic lateral sclerosis (ALS), and in 
organic brain injury associated with hypoxia, ischemia, and 
hypoglycemia.34,37–39
Figure 1 l-cysteine.Drug Design, Development and Therapy 2009:3 123
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There are several putative mechanisms of l-cysteine 
toxicity; during ischemic brain damage,  l-cysteine is 
released in the extracellular fluid from glial cells by a 
mechanism that involves γ-glutamyltransferase (γ-GT).40 
This mechanism may involve the breakdown of glutathione 
by γ-GT, in addition to l-cysteine release from cells, leading 
to excitotoxic effects. The second mechanism may involve 
the interaction of l-cysteine with the n-methyl-d-aspartate 
(NMDA) receptors, which results in NMDA receptor 
activation and massive influx of Ca2+. The prolonged 
NMDA receptor overexcitation and massive secondary 
release of Ca2+ from intracellular stores leads to cell death.41 
l-cysteine thus enhances the glutamate- and NMDA-evoked 
neuronal influx of Ca2+, leading to destruction of neurons 
when l-cysteine is administered orally in high doses to 
laboratory animals with underdeveloped blood–brain barriers 
(such as infant mice).42
The third putative mechanism may involve oxygen free 
radical generation.43 The excess oxygen free radicals may 
then cause overactivation of NMDA receptors via lipid 
peroxidation. Additionally, the neurotoxicity of l-cysteine 
may be mediated by the increased extracellular concentration 
of glutamate as a result of the inhibition of glutamate neuronal 
reuptake by l-cysteine.44 Because l-cysteine is metabolized 
to toxic oxidized products such as s-sulfocysteine and 
cysteate, such products act at glutamate receptors and 
mediate neurotoxic effects.45 Subcutaneous administration 
of 0.5 to 1.5 mg/g body weight of l-cysteine to 4- to 
6-day-old mice (this dose is approximately 50–75 times 
greater than the reversal dose of 10–20 mg/kg) resulted in 
severe hypoglycemia and central neural damage, which 
was glucose-reversible.46 It was thus hypothesized that 
cysteine-induced neurotoxicity was linked to hypoglycemia. 
Excess dietary l-cysteine (30 gm/kg for three days) also 
caused lethal metabolic acidosis in chicks, despite being fed 
an otherwise nutritionally adequate meal diet.47
Finally, l-cysteine interacts with catecholamines (dopamine, 
norepinephrine, epinephrine) and may result in covalent binding 
of catecholamines to cysteine residues. l-cysteine thus forms 
neurodestructive cysteinylcatechols such as cysdopac,48 which 
may inhibit mitochondrial respiration.49 For a comprehensive 
review on the mechanisms of cysteine-induced neurotoxicity, 
see Janaky and colleagues.49 Despite the multiple potential side 
effects, l-cysteine is added to total parenteral nutrition solutions 
(∼300 mg of cysteine/L) to enhance calcium and phosphate 
solubility, because cysteine lowers the pH (cysteine pH is 1.0) 
of the solution. Use of these solutions, however, has been 
associated with the development of acidosis in infants.50
In view of the multiple putative mechanisms by which 
l-cysteine could be neuroexcitatory and neurotoxic, there 
are still many unanswered questions regarding the safety 
of giving humans exogenous cysteine in doses required for 
adequate antagonism of the new chlorofumarate muscle 
relaxants gantacurium and/or AV002. These questions 
would be particularly applicable in clinical scenarios such 
as trauma, neurosurgery, obstetrics, to name a few, as well 
as specific patient populations such as patients at extremes 
of age, those with diabetes, treated hypertensive patients, or 
those with pre-existing neurodegenerative disease. Clearly, 
before the introduction of cysteine into clinical use as a 
reversal agent (antagonist of mixed-onium chlorofumarates 
gantacurium and AV002), significant preliminary work 
needs to be done. Absorption, distribution, metabolism 
and excretion (A.D.M.E.) data from animals will need 
to be investigated as part of the New Drug Application 
process.
Antagonism of neuromuscular block
In laboratory animals (Rhesus monkeys), doses of  gantacurium 
eight times greater than those required for 95% depression 
of the neuromuscular response (ED95) have a duration of 
action of approximately 14 minutes. Cysteine reversal 
(10 mg/kg) results in return of complete neuromuscular 
function in 1–2 min.13 Similarly, cysteine (50 mg/kg dose) 
will decrease the duration of neuromuscular block of AV002 
from 30 min to 2–3 min.13
Pharmacokinetics:  animal data
Cysteine, with a reported half-life of 1–2 hours, given to 
male Rhesus monkeys accelerated the recovery times from 
profound neuromuscular blockade induced by AV002.51 
Cysteine 100 mg/kg given to four dogs anesthetized with 
isoflurane/nitrous oxide produced a brief (2–3 min) decline 
in mean arterial blood pressure, followed by a sustained 
increase.52 This pattern was accompanied by minimal changes 
in heart rate and systemic vascular resistance, stroke vol-
ume, left ventricular ejection fraction, and left ventricular 
inotropy (assessed as change in pressure/change in time 
normalized to left ventricular end-diastolic volume). The 
authors noted that the hemodynamic effects reported were 
consistent with both direct and reflex responses in combina-
tion with a centrally-mediated vasopressin release.52 Doses 
ranging from 20 to 50 mg/kg of cysteine resulted in minimal 
changes in mean arterial blood pressure and heart rate. Only 
a 100 mg/kg dose of cysteine resulted in a 14.6% increase in 
mean arterial pressure and a 5.2% decrease in heart rate.53 Drug Design, Development and Therapy 2009:3 124
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In studies of reversal of neuromuscular block in Rhesus 
monkeys, adult animals received cysteine (50–200 mg/kg) 
every 4–6 weeks for over three years. There have been no 
changes in general physical exam, body weight, or serum 
chemistries (hematology, liver or kidney function tests).   
Similarly, there have been no reports of organ damage or 
histopathologic changes in adult laboratory rats and dogs 
given intravenous cysteine (studies performed at Charles 
River Laboratories in Shrewsbury, MA.; IND report submit-
ted to FDA, J. J. Savarese, MD, personal communication).
Sugammadex
Pharmacology
Sugammadex is a synthetic γ-cyclodextrin, and the first 
compound in a new class of neuromuscular reversal drugs 
called SRBAs.16,54–56 Cyclodextrins are cyclic dextrose units 
joined through 1–4 glycosyl bonds, and are produced from 
starch or starch derivates using cyclodextrin glycosyltrans-
ferase. The three most common cyclodextrins consist of 
six, seven, or eight cyclic oligosaccharides and are named 
α-, β-, or γ-cyclodextrin, respectively. Cyclodextrins can be 
formed naturally from bacteria, or they can be manufactured 
synthetically.
The molecular characteristics of unmodified γ-cyclodextrin 
(A) and modified γ-cyclodextrin (sugammadex) (B) are shown 
in Figure 2.56 The cyclodextrin three-dimensional structure 
resembles a doughnut, in which the cavity is hydrophobic 
and the exterior is hydrophilic because of the presence of 
charged hydroxyl groups. Hydrophobic interactions were 
designed to trap the drug into the cyclodextrin cavity, 
resulting in the formation of a very stable, water-soluble 
guest–host complex.
Compared with α- and β-cyclodextrins, γ-cyclodextrin is 
designed to better fit the steroidal muscle relaxant molecule; 
sugammadex, in particular, has a larger lipophilic cavity 
(7.5–8.3 Å diameter) than the α- and β-cyclodextrins 
(whose internal cavity diameter is less than 6.5 Å). This 
cavity size is better suited to incorporate (encapsulate) 
rocuronium and vecuronium molecules, whose width is 
approximately 7.5 Å.56 For sugammadex, the specificity 
toward steroidal muscle relaxants was further increased 
by the addition of eight polar hydroxyl side chains. This 
modification allowed the four hydrophobic steroidal rings 
of rocuronium (or vecuronium) to be better accommodated 
within the hydrophobic cavity of the sugammadex molecule, 
while the negatively charged carboxyl groups at the end of 
the eight side chains allow enhanced electrostatic binding to 
the positively charged quaternary nitrogen of rocuronium.16,56 
Additionally, the repellent forces of the negatively charged 
carboxyl groups keep the cavity open and maintain molecular 
structural integrity.
The resulting sugammadex compound has a molecular 
weight of 2,178 Da; it is highly water-soluble and the aqueous 
solution of sugammadex has a pH of approximately 7.5, 
with an osmolality of 300–500 mOsmol/kg. Because of the 
intermolecular (van der Waals) forces, the thermodynamic 
(hydrogen) bonds, and the hydrophobic interactions, sugam-
madex forms very tight complexes at a 1:1 ratio with steroidal 
neuromuscular blocking agents (rocuronium  vecuronium 
 pancuronium).16,54–56 The sugammadex–rocuronium com-
plex has a very high association rate (an association constant 
of 107 M–1 as determined by isothermal titration calorimetry) 
and a very low dissociation rate. It is estimated that only one 
out of every 25 million sugammadex–rocuronium complexes 
dissociates.
Figure 2 Cyclodextrin, sugammadex. A) Unmodified γ-cyclodextrin. B) Modified 
γ-cyclodextrin.
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Sugammadex has a different mechanism of pharmacologic 
reversal than the anticholinesterase agents, and thus exerts 
no effect on any receptor system in the body. Because of 
this, administration of sugammadex does not necessitate the 
co-administration of anticholinergic drugs, thus eliminating 
their undesirable adverse effects. In addition, the unique and 
selective mechanism of reversal by encapsulation is indepen-
dent of the depth of neuromuscular block or the degree of 
spontaneous recovery; thus, reversal can be accomplished at 
any depth of neuromuscular block.
Pharmacodynamics
Because of its molecular structure, sugammadex may interact 
with drugs other than the intended steroidal nondepolarizing 
muscle relaxants. Among the compounds that may affect the 
efficacy of sugammadex are toremifene, flucloxacillin and 
fusidic acid. Toremifene may displace rocuronium because 
of its high affinity for sugammadex. Thus, administra-
tion of toremifene within 24 hours of surgery may delay 
reversal of neuromuscular block.57 For the intravenous admin-
istration of flucloxacillin and fusidic acid, the displacement of 
vecuronium or rocuronium from sugammadex may also result 
in delay in recovery of neuromuscular function, but these two 
drugs should be avoided only for six hours postoperatively.57 
For all these drugs, a period of surveillance to exclude potential 
delay in reversal and occurrence of respiratory compromise is 
recommended. The interaction of sugammadex with oral hor-
monal contraceptives has the effect of one missed daily dose 
(for either the combined or progestogen-only contraceptive).
In general, sugammadex has not been reported to interfere 
with most laboratory tests; the possible exceptions are serum 
progesterone assay and some coagulation parameters (activated 
partial thromboplastin time, prothrombin time/international 
normalized ratio). This interference was observed in plasma 
samples in which the concentration of sugammadex was in 
the same range as that obtained after a dose of 16 mg/kg. The 
clinical relevance of these findings is uncertain, however, as 
this has not been studied in patients.57
Antagonism of neuromuscular block
The reversal activity of sugammadex is selective for 
steroidal neuromuscular blocking agents. Sugammadex has 
no affinity for isoquinolinium agents such as mivacurium 
or atracurium.58 Sugammadex, used in recommended doses 
of 2–16 mg/kg, is capable of reversal (defined as return 
of TOF ratio to 0.9) of any depth of neuromuscular 
block induced by rocuronium or vecuronium within three 
minutes.59–61 Intravenous administration of sugammadex 
results in rapid removal of free rocuronium or vecuronium 
molecules from the plasma, creating a concentration 
gradient that favors the movement of the remaining unbound 
molecules away from the neuromuscular junction and into 
the plasma. Here, the unbound rocuronium or vecuronium 
molecules are encapsulated by the remaining unbound 
sugammadex molecules. At the same time, the unbound (as 
well as the complexed) sugammadex molecules also enter 
the extracellular volume along the concentration gradient 
and form new complexes with the unbound rocuronium or 
vecuronium. Therefore, the neuromuscular blocking actions 
of the unbound neuromuscular agents are terminated rapidly 
because of their diffusion away from the neuromuscular 
junction back into the plasma. This results in an increase in 
the total plasma concentration of rocuronium (both unbound 
and bound to sugammadex)62 or vecuronium.
The efficacy of reversal with sugammadex has been studied 
in three clinical conditions that mirror the recommended 
dose ranges: 1) if reversal of shallow block (defined as 
spontaneous recovery to reappearance of the second twitch, 
T2, of the TOF) is desired, a dose of 2 mg/kg is recom-
mended; 2) for reversal of deep block (defined as spontane-
ous recovery to at least 1–2 post-tetanic counts, PTC1–2), a 
dose of 4 mg/kg is recommended; and 3) for “rescue” in 
the scenario of a large dose administration when there is 
no evidence of any spontaneous recovery in the “cannot 
intubate-cannot ventilate” setting, a dose of 16 mg/kg is 
recommended.57 These doses of sugammadex were used for 
subsequent clinical trials that formed the basis for approval 
by the European Medicines Agency (EMEA).
Based on the published tolerance intervals (97.5% 
confidence level), a dose of 2 mg/kg of sugammadex for 
reversal of shallow block (return of T2) will result in complete 
reversal (TOF  0.9) in 90% of patients within three minutes 
after rocuronium administration, and within 5.9 min after 
vecuronium administration.63 Based on the same tolerance 
intervals (97.5% confidence level), a dose of 4 mg/kg of 
sugammadex for reversal of deep block (administered at 
PTC1–2) will result in complete reversal (TOF  0.9) in 90% 
of patients within 3.9 min after rocuronium administration 
(no confidence intervals were calculated for vecuronium at 
this deep level of block).63 Finally, for immediate reversal 
of block (within 3–5 minutes of administration of 1.2 mg/kg 
of rocuronium), the mean time for complete spontaneous 
recovery was 122.5 minutes (range, 87–156 minutes), while 
a dose of sugammadex of 16 mg/kg resulted in complete 
recovery within a mean of 1.6 min (range 0.7–6.9 min) 
(Tables 1, 2).63Drug Design, Development and Therapy 2009:3 126
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With profound blockade induced by large doses of 
rocuronium or vecuronium, larger doses of sugammadex 
(8–16 mg/kg) are required for adequate and rapid recovery. 
For instance, when comparing the speed of recovery from 
1.2 mg/kg of rocuronium followed three minutes later by 
16 mg/kg of sugammadex with the speed of spontaneous 
recovery from 1.0 mg/kg of succinylcholine, the total time 
from the administration of rocuronium until recovery of 
the TOF to  0.9 was less than that needed for a similar 
degree of spontaneous recovery from the succinylcholine-
induced block.61
Since all drugs behave in a dose-response manner,64 
rare instances of re-paralysis (“recurarization”) have been 
reported in human and animal studies after administration 
of inadequate doses (2 mg/kg) of sugammadex.58–60,62,65–67 
A temporary decrease in TOF response was thus observed after 
reversal of muscle relaxation with a small dose (0.5 mg/kg) 
of sugammadex administered 42 minutes after 0.9 mg/kg of 
rocuronium, indicating there were insufficient numbers of 
sugammadex molecules available to encapsulate all existing 
rocuronium molecules.68
Pharmacokinetics and metabolism
Sugammadex has no affinity for binding to plasma 
proteins.60,65,69 When administered to volunteers who had 
not received a neuromuscular blocking agent, doses of 
0.1–8.0 mg/kg of sugammadex had a clearance rate of 
88 mL/minute, an elimination half-life of 1.8 hours, and a 
volume of distribution of 11–14 L.65,70 Approximately 75% 
of the dose was eliminated renally. Between 59% and 80% of 
the sugammadex dose is excreted renally in the first 24 hours 
after administration.65 The kinetics of sugammadex appeared 
to be linear when the sugammadex dose was increased from 
0.1 to 8.0 mg/kg.65
In the absence of sugammadex, rocuronium is eliminated 
mainly by biliary excretion (75%) and to a lesser degree 
by renal and fecal routes.71 In contrast, the plasma clearance 
of sugammadex alone is approximately one third that of 
rocuronium alone.72 Because of the soluble nature of the 
sugammadex–rocuronium complex, urinary excretion of 
the complex is the major route for the elimination of the 
complexed rocuronium (65%–97% of the administered dose 
is recovered in urine).65,72
Metabolism of sugammadex is at most very limited, and 
the drug is thus eliminated in the urine mostly unchanged. 
In patients with substantial renal impairment, compared 
with healthy subjects, the clearance of sugammadex 
and rocuronium was decreased by a factor of 17 and 4, 
respectively, and the elimination half-life was increased by 
a factor of 15 and 2.5, respectively.73 Dialysis for removal 
of sugammadex and rocuronium from the plasma is not 
consistently effective. Therefore, it has been recommended 
that sugammadex be avoided in patients with a creatinine 
clearance of 30 mL/minute.
Sugammadex is not metabolized by the liver, so it has not 
been evaluated specifically in patients with hepatic impairment; 
however, caution is recommended in the use of sugammadex 
in patients with liver failure.57 The pharmacokinetic response 
to sugammadex in elderly patients depends mostly on adequate 
renal function, and no changes in the metabolism or excretion 
of sugammadex are expected based solely on patient age.
A total of 77 patients with pulmonary disease such 
as asthma, bronchitis and chronic obstructive pulmonary 
disease, tolerated the administration of sugammadex without 
significant problems.74 However, bronchospasm was reported 
Table 2 vecuronium administration: summary of time (in minutes) 
from administration at shallow block (reappearance of    T2) and deep 
block (PTC1–2) until recovery (TOF  0.9)
Placebo 2.0 mg/kg 4 mg/kg 8 mg/kg
Shallow block
n 19 21 26 4
Mean (±SD) 74.2 (26.8) 2.8 (1.3) 2.3 (1.5) 1.4 (0.5)
range 27–141 1.3–7.1 1.0–8.5 0.8–2.0
Deep block
n – 21 18 20
Mean (±SD) – 12.4 (32.0) 3.2 (2.8) 2.3 (2.7)
range – 1.5–136.1 0.9–11.7 0.7–13.5
Abbreviations: PTC, post-tetanic counts; SD, standard deviation;   TOF, train-of-four.
Table 1 rocuronium administration: summary of time (in minutes) 
from administration at shallow block (reappearance of   T2) and deep 
block (PTC1–2) until recovery (TOF  0.9)
Placebo 2.0 mg/kg 4 mg/kg 8 mg/kg
Shallow block
n 25 38 39 –
Mean (±SD) 60.0 (38.8) 1.6 (0.7) 1.4 (0.7) –
range 15–153 0.7–4.8 0.7–4.8 –
Deep block
n 3 34 31 34
Mean (±SD) 35.6 (9.0) 3.6 (2.6) 1.8 (1.0) 1.3 (0.4)
range 30–46 1.1–15.2 0.8–4.5 0.6–2.4
Abbreviations: PTC, post-tetanic counts; SD, standard deviation;   TOF, train-of-four.Drug Design, Development and Therapy 2009:3 127
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twice in patients with asthma, both in the 4 mg/kg group, 
and both required treatment, but had no sequelae.74 Several 
other detailed articles have been published recently on 
sugammadex.61,75
Safety
The safety of sugammadex has been evaluated based on an 
integrated safety database of approximately 1,700 patients 
and 120 volunteers. The most commonly reported adverse 
reaction, dysgeusia (metal or bitter taste), was generally 
reported after doses of 32 mg/kg of sugammadex or higher. 
In a few individuals, allergic-like reactions (ie, flushing, 
erythematous rash) following sugammadex were reported. 
In one of these individuals, a mild allergic reaction was 
confirmed.57
Several studies have investigated the effects of 
sugammadex on the QTc interval. All of the published data 
to this point suggest that sugammadex does not significantly 
prolong the QTc interval. Prolongation was defined as an 
absolute QTc value  500 msec, or an increase in baseline 
QTc of at least 60 msec.57 There also was no evidence that 
sugammadex may predispose patients to QTc prolongation 
when sugammadex was administered in conjunction with 
drugs known for their propensity to prolong the QTc (such 
as propofol and sevoflurane).57 Even in a subgroup of patients 
with severe heart disease, sugammadex did not induce QTc 
prolongation.76
There have been no reports of clinically significant effects 
of sugammadex on hemodynamic variables (blood pressure, 
heart rate), respiration, or thermoregulation.57
Common (incidence 1%–10%) adverse effects are similar 
for sugammadex and placebo. They include anesthetic 
complications (movement, coughing, grimacing, or suckling 
on the tracheal tube). While sugammadex has been approved 
by EMEA for clinical use in several European countries 
last summer, the US Food and Drug Administration issued 
a “not approvable” letter (August 2008), citing concerns 
about hypersensitivity and allergic reactions. It is hoped that 
additional clinical and safety data will soon become available 
from the European experience, and may influence the US 
Food and Drug Administration decisions on the approval 
of sugammadex.
Conclusion
Despite the significant advances in the chemistry of 
neuromuscular blocking agents, the promise of the “perfect” or 
“ideal” drug remains illusory. However, it is incontroversial that 
the significant improvements made in the last few decades in the 
pharmacology of relaxants and reversal agents have improved 
clinical care and patient safety. Even if we do not yet have a 
fast-onset, highly reliable, short duration, rapidly reversible, 
noncumulative nondepolarizing drug, the characteristics of the 
“perfect” drug are within reach. By combining the rapid onset 
of a drug like rocuronium (or gantacurium or AV002) with the 
fast reversal and stable hemodynamic profile of the selective 
reversal agent sugammadex (or cysteine and glutathione), the 
promise of rapid onset of block with rapid and reliable offset 
has become reality. And because reversal by both sugammadex 
and cysteine is independent of the depth of neuromuscular 
block, the morbidity associated with the “cannot-ventilate/
cannot-intubate” clinical scenario is avoided; moreover, 
the lack of disassociation of the rocuronium/sugammadex 
complex, and the lack of neuromuscular blocking potency of 
the chlorofumarates’ break-down products, will ensure that 
the recurrence or persistence of residual weakness will become 
an oddity of the past.
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